Cardio-TriTest vs FFRangio System
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Cardio-TriTest focuses on early and comprehensive cardiovascular disease detection in primary care through non-invasive bio-signal analysis. In contrast, the FFRangio System provides AI-powered guidance for optimizing percutaneous coronary intervention (PCI) decisions within a cath lab. While both utilize AI in cardiology, they address different clinical needs and stages of patient care.
Choose Cardio-TriTest if…
Choose Cardio-TriTest if your primary objective is early, non-invasive, and comprehensive cardiovascular disease detection in a primary care or general clinical setting. This device is ideal for screening a broad patient population by combining and visually correlating multiple heart bio-signals (ECG, PCG, MCG) with AI-powered analysis to identify potential issues before they become critical.
View Cardio-TriTest →Choose FFRangio System if…
Choose the FFRangio System if you require advanced, wire-free, and drug-free functional assessment of coronary artery disease to guide percutaneous coronary intervention (PCI) decisions within a cath lab environment. This system provides real-time FFRangio values and insights to optimize treatment strategies and confirm the efficacy of interventions for patients undergoing revascularization procedures.
View FFRangio System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cardio-TriTest | FFRangio System |
|---|---|---|
| Pricing | Unknown | Contact vendor for pricing information. |
| Deployment | On-premise (device) | SaaS, on-prem, hybrid |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Unknown | Cleared AI-estimated |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cardio-TriTest | FFRangio System |
|---|---|---|
| Product Name | Cardio-TriTest | FFRangio System |
| Company | Cardio-Phoenix Inc. | CathWorks |
| Primary Function/Description | AI-powered 3-in-1 diagnostic device combining ECG, PCG, and MCG to synchronize and visually correlate heart bio-signals for earlier and more comprehensive cardiovascular disease detection in primary care. | Delivers wire-free and drug-free 3D FFR guidance, providing accurate multi-vessel FFR results and advanced insights to quickly optimize and confirm PCI decisions for patients with coronary artery disease. |
| Key Diagnostic Technologies/Features | 3-in-1 diagnostic device (ECG, PCG, MCG); Synchronized bio-signal acquisition; Visual correlation of heart bio-signals; AI-powered analysis for heart disease detection; Non-invasive test procedure. | Real-time FFRangio values at every point on the coronary tree; Simulated pullback curve; Lesion Impact feature to assess residual ischemia; Integrated sizing tool for non-invasive lesion measurements; Eliminates the need for invasive pressure wires, drugs, or a guide catheter. |
| Specialties | Cardiology, Family Medicine, Internal Medicine | Cardiology |
| Categories | Cardiology AI | Cardiology AI, Surgical AI |
Videos
Demos, reviews, and walkthroughs featuring Cardio-TriTest and FFRangio System.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
Cardio-TriTest is designed for primary care, offering a non-invasive 3-in-1 diagnostic test (ECG, PCG, MCG) for earlier and more comprehensive cardiovascular disease detection, fitting into routine office visits. The FFRangio System integrates seamlessly into the cath lab, providing real-time, wire-free, and drug-free 3D FFR guidance to optimize and confirm PCI decisions during interventional procedures.
Cardio-TriTest is best suited for primary care, family medicine, and internal medicine settings to screen and detect cardiovascular disease earlier in a broad patient population using non-invasive methods. The FFRangio System is primarily designed for cardiologists in the cath lab to guide percutaneous coronary intervention (PCI) decisions for patients with known coronary artery disease, eliminating the need for invasive pressure wires.
Cardio-TriTest combines and visually correlates three distinct heart bio-signals (ECG, PCG, MCG) with AI-powered analysis to provide a more comprehensive and potentially earlier detection of cardiovascular disease. The FFRangio System utilizes AI to deliver accurate multi-vessel FFR results and advanced insights, including real-time FFRangio values and simulated pullback curves, to optimize PCI decisions.
Cardio-TriTest, as a diagnostic device, would typically generate reports that can be integrated into an EHR, though specific integration depth is not detailed in the provided information. The FFRangio System features seamless integration with cath lab boom and PACS, suggesting robust capabilities for incorporating its real-time FFRangio values and insights directly into imaging and patient records.
Cardio-TriTest is described as a non-invasive test procedure, implying a relatively straightforward operation for acquiring 3-in-1 bio-signals, though specific user interface details are not provided. The FFRangio System features an 'intuitive user interface' and AI assistance for quick angiogram analysis, suggesting a design focused on ease of use within the cath lab environment.
By offering a 3-in-1 non-invasive diagnostic in primary care, Cardio-TriTest aims for earlier and more comprehensive detection, potentially streamlining initial cardiovascular assessments. The FFRangio System eliminates the need for invasive pressure wires and drugs, providing real-time 3D FFR guidance, which can significantly optimize and accelerate PCI decision-making in the cath lab.